Product news from the 04/21/06 News Brief

Share this article:
The FDA has granted Fast Track designation to Schering-Plough’s investigational oral thrombin receptor antagonist (SCH 530348), currently in Phase II clinical development for secondary prevention of cardiovascular morbidity and mortality outcomes in at-risk patients.
Share this article:

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.